Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Rubio · SciRah

Researcher profile · Semantic Scholar

M. Rubio

Share profile

M. Rubio — researcher profile on SciRah

h-index: 11
Works: 45
Citations: 939

Most-cited papers

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
J. Trigo, V. Subbiah, B. Besse, V. Moreno +29 more
2020The Lancet Oncology401 citations
Semantic Scholar
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.
A. González-Martín, E. Calvo, I. Bover, M. Rubio +12 more
2005Annals of Oncology130 citations Open access
Semantic Scholar
The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer
F. C. Muñoz-Casares, S. Rufián, M. Rubio, Carlos J. Díaz +5 more
2009Clinical and Translational Oncology76 citations
Semantic Scholar
Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
F. C. Muñoz-Casares, F. J. Medina-Fernández, Á. Arjona-Sánchez, Á. Casado-Adam +6 more
2016European Journal of Surgical Oncology56 citations
Semantic Scholar
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
K. Lindemann, G. Kristensen, M. Mirza, Leo Davies +12 more
2016Annals of Oncology42 citations Open access
Semantic Scholar
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
V. Subbiah, L. Paz-Ares, B. Besse, V. Moreno +30 more
2020Lung Cancer37 citations Open access
Semantic Scholar
Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study
F. C. Muñoz-Casares, S. Rufián, Á. Arjona-Sánchez, M. Rubio +8 more
2011Cancer Chemotherapy and Pharmacology33 citations Open access
Semantic Scholar
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
T. Herzog, S. Pignata, S. Ghamande, M. Rubio +20 more
2023Gynecologic Oncology20 citations
Semantic Scholar
Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).
F. Joly, I. Ray-Coquard, M. Rubio, X. Paoletti +15 more
2023Journal of Clinical Oncology15 citations
Semantic Scholar
An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
I. Romero, M. Rubio, M. Medina, X. Matías-Guiu +12 more
2020Gynecologic Oncology15 citations
Semantic Scholar
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)
B. Tavira, T. Iscar, L. Manso, A. Santaballa +11 more
2023Clinical Cancer Research12 citations Open access
Semantic Scholar
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
I. Vergote, E. Van Nieuwenhuysen, Á. Casado, A. Laenen +16 more
2023Gynecologic Oncology10 citations Open access
Semantic Scholar
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
A. Poveda, Raquel López-Reig, A. Oaknin, A. Redondo +9 more
2022Cancers10 citations Open access
Semantic Scholar
Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)
M. Rubio, M. J. Lecumberri, S. Varela, J. Alarcón +8 more
2020Gynecologic Oncology Reports10 citations Open access
Semantic Scholar
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
I. Romero, Pedro Mallol, A. Santaballa, J. D. del Campo +16 more
2019Anti-Cancer Drugs10 citations
Semantic Scholar
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03
J. García-Donas, A. Hurtado, L. Garrigós, A. Santaballa +18 more
2023Clinical and Translational Oncology7 citations
Semantic Scholar
Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network
J. López-Guerrero, M. Mendiola, J. Pérez-Fidalgo, I. Romero +17 more
2022Cancers6 citations Open access
Semantic Scholar
19th International Meeting of the European Society of Gynecological Oncology (ESGO 2015)
K. Lindeman, G. Kristensen, M. Mirza, L. Davies +12 more
2015International Journal of Gynecologic Cancer6 citations Open access
Semantic Scholar
Symptoms and adverse effects with chemotherapy ± bevacizumab for platinum-resistant recurrent ovarian cancer: Analysis of the phase III AURELIA trial
F. Hilpert, M. Fabbro, M. Rubio, A. Reuss +6 more
20136 citations
Semantic Scholar
Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study
M. Rubio, A. Manzano, L. D. de Sande, P. Estévez-García +11 more
2024BMC Cancer5 citations Open access
Semantic Scholar
Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus
A. Redondo, P. Barretina, Alejandro Pérez-Fidalgo, M. Rubio +1 more
2023Journal of Gynecologic Oncology5 citations Open access
Semantic Scholar
Management of advanced ovarian cancer in Spain: an expert Delphi consensus
A. Redondo, A. Oaknin, M. Rubio, M. Barretina-Ginesta +6 more
2021Journal of Ovarian Research5 citations Open access
Semantic Scholar
ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
C. Marth, C. Vulsteke, M. Rubio, V. Makker +11 more
2019Annals of Oncology5 citations Open access
Semantic Scholar
Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)
I. Romero, M. Rubio, R. Serrano, M. Medina +14 more
20163 citations Open access
Semantic Scholar
Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01)
J. García-Donás, L. Garrigós, Nuria Lainez, A. Santaballa +16 more
2024Clinical and Translational Oncology2 citations
Semantic Scholar
P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose
J. M. T. Trigo Perez, V. Subbiah, B. Besse, V. Moreno +26 more
2019Journal of Thoracic Oncology2 citations Open access
Semantic Scholar
Ketoconazole as inhibitor of the enzyme CYP17 in locally advanced or disseminated granulosa cell tumors of the ovary (the GreKo I study) (gethi 11-03).
L. Garrigós, A. Hurtado, A. Santaballa, A. Redondo +15 more
20142 citations
Semantic Scholar
Trabectedin plus PLD versus PLD monotherapy in patients with platinum-sensitive relapsed ovarian cancer: a cost-effectiveness analysis in Spain
J. Montalar, G. Cajaraville, M. Carreras, M. Rubio +3 more
20122 citations
Semantic Scholar
Emetic control in breast cancer patients receiving iv CMF.
M. Martín, E. Aranda, E. Diazrubio, A. Casado +6 more
1996Oncology Report2 citations
Semantic Scholar
Prevention of Highly Emetogenic Chemotherapy-Induced Vomiting: A Double Blind, Randomized Crossover Study to Compare Pancopride (LAS 30451) and Pancopride plus Dexamethasone
E. Aranda, I. Barneto, M. Rubio, Rosario Gonzalez +2 more
1995Tumori2 citations
Semantic Scholar
Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.
A. Poveda, S. Lheureux, N. Colombo, D. Cibula +14 more
Journal of Clinical Oncology2 citations
Semantic Scholar
MO01.08 Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders
V. Subbiah, L. Paz-Ares, B. Besse, V. Moreno +19 more
20211 citations Open access
Semantic Scholar
Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study)
A. Redondo, R. Gironés, N. Ruiz, M. Iglesias +8 more
2021European Journal of Gynaecological Oncology1 citations Open access
Semantic Scholar
MO01.09 Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics
J. Sands, L. Paz-Ares, B. Besse, Solange Peters +22 more
20211 citations Open access
Semantic Scholar
Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).
J. Pérez-Fidalgo, A. Cortés-Salgado, Y. Garcia, M. Iglesias +8 more
20211 citations
Semantic Scholar
Dovitinib as second-line therapy in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or non-mutated advanced and/or metastatic endometrial cancer (EC): A single-arm, multicenter, phase II study.
G. Konecny, N. Finkler, Agustin Garcia, F. Raspagliesi +8 more
20131 citations
Semantic Scholar
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer
T. Herzog, S. Pignata, S. Ghamande, M. Rubio +20 more
2021Gynecologic Oncology0 citations
Semantic Scholar
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensit
T. Herzog, S. Pignata, S. Ghamande, M. Rubio
20210 citations
Semantic Scholar
323 ENGOT-en9/LEAP-001: a phase 3 study of first-line pembrolizumab plus lenvatinib compared with chemotherapy in advanced or recurrent endometrial cancer
L. Randall, C. Marth, C. Vulsteke, M. Rubio +12 more
20200 citations Open access
Semantic Scholar
ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer
C. Marth, C. Vulsteke, M. Rubio, V. Makker +11 more
2020Gynecologic Oncology0 citations
Semantic Scholar
Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study).
I. Romero, M. Rubio, M. Medina, R. Serrano +16 more
20180 citations
Semantic Scholar
Killer-cell Inmunoglobulin-like Receptor (KIR) genes as a predictor of response to the anti-HER therapy in solid tumors.
Cristina Morales-Estévez, B. Manzanares-Martín, J. R. De la Haba-Rodríguez, R. González-Fernández +10 more
20160 citations
Semantic Scholar
2703 Computed tomography is more sensitive than CA 125 in detecting disease progression in patients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial
K. Lindeman, G. Kristensen, M. Mirza, L. Davies +11 more
20150 citations
Semantic Scholar
A multicenter pilot study of adjuvant docetaxel, epirubicin and cyclophosphamide (TEC) in patients (p) with stage II/III and node-positive breast cancer (BC)
J. Mayordomo, A. Lorenzo, A. Modolell, I. Alvarez +7 more
20070 citations
Semantic Scholar
Prolonged infusion of gemcitabine in patients with platinum resistant or refractory recurrent ovarian carcinoma: A phase II study Of GEICO (Spanish Group for investigation on ovarian cancer)
B. Ojeda, A. González-Martín, B. Mellado, I. Bover +6 more
20050 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. González-Martín×12
Invite
A. González-Martín — researcher profile on SciRah
I. Romero×10
Invite
I. Romero — researcher profile on SciRah
A. Santaballa×8
Invite
A. Santaballa — researcher profile on SciRah
S. Pignata×7
Invite
S. Pignata — researcher profile on SciRah

×7

Invite

A. Redondo — researcher profile on SciRah

Invite

I. Bover — researcher profile on SciRah

Invite

E. Guerra — researcher profile on SciRah

Invite

A. Poveda — researcher profile on SciRah

Invite

V. Subbiah — researcher profile on SciRah

Invite

B. Besse — researcher profile on SciRah

Invite

M. Sala — researcher profile on SciRah

Invite

C. Kahatt — researcher profile on SciRah